Destiny Pharma Plc DEST
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of Destiny Pharma Plc shares you hold and we'll calculate your dividend payments:
Sign up for Destiny Pharma Plc and we'll email you the dividend information when they declare.
Add Destiny Pharma Plc to receive free notifications when they declare their dividends.
Your account is set up to receive Destiny Pharma Plc notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no Destiny Pharma Plc dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0p | — |
| 2007 | 0.0p | 0% |
| 2008 | 0.0p | 0% |
| 2009 | 0.0p | 0% |
| 2010 | 0.0p | 0% |
| 2011 | 0.0p | 0% |
| 2012 | 0.0p | 0% |
| 2013 | 0.0p | 0% |
| 2014 | 0.0p | 0% |
| 2015 | 0.0p | 0% |
| 2016 | 0.0p | 0% |
| 2017 | 0.0p | 0% |
| 2018 | 0.0p | 0% |
| 2019 | 0.0p | 0% |
| 2020 | 0.0p | 0% |
| 2021 | 0.0p | 0% |
| 2022 | 0.0p | 0% |
| 2023 | 0.0p | 0% |
| 2024 | Sign Up Required | |
Destiny Pharma Plc Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 22 December 2023
- 52 Week Low
- 0.0% on 22 December 2023
- Next Ex-Div-Date Countdown
- Sign Up Required
About Destiny Pharma Plc
Destiny Pharma plc is a clinical stage, biotechnology company. The Company is engaged in the discovery, development, and commercialization of novel medicines with a focus on infection prevention. It is focused on developing novel antimicrobial drug from its exeporfinium chloride platform and also from two biotherapeutic products. Its pipeline includes XF-73 nasal gel, NTCD-M3, and XF-73 dermal. XF-73 nasal gel is developed for the prevention of post-surgical staphylococcal infections. NTCD-M3, which is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins. NTCD-M3 is used for the prevention of C. difficile infection (CDI) recurrence. XF-73 derma is developed for the prevention and treatment of serious infections associated with wounds and ulcers such as diabetic foot ulcers (DFUs). The Company is co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- United Kingdom
- Share Price
- £0.03 (yesterday's closing price)
- Shares in Issue
- 96 million
- Market Cap
- £3mn
- 0
- Market Indices
- none
